Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Update

Bionano Genomics, Inc. (NASDAQ:BNGO) saw a significant drop in short interest in August. As of August 15th, there was short interest totalling 4,230,000 shares, a drop of 5.4% from the July 31st total of 4,470,000 shares. Currently, 6.2% of the company’s stock are sold short. Based on an average daily volume of 1,780,000 shares, the short-interest ratio is currently 2.4 days.

Bionano Genomics Stock Up 1.4 %

Bionano Genomics stock opened at $0.49 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.63 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $42.14 million, a P/E ratio of -0.08 and a beta of 2.40. The firm has a 50 day moving average price of $0.57 and a 200-day moving average price of $0.85. Bionano Genomics has a twelve month low of $0.31 and a twelve month high of $4.20.

Bionano Genomics (NASDAQ:BNGO) last released its earnings results on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter. Bionano Genomics had a negative return on equity of 151.27% and a negative net margin of 557.98%. The firm had revenue of $7.77 million during the quarter. As a group, equities analysts predict that Bionano Genomics will post -1.59 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. BTIG Research reduced their target price on Bionano Genomics from $3.00 to $2.00 and set a “buy” rating for the company in a report on Thursday, May 16th. Scotiabank reaffirmed a “sector perform” rating and set a $1.00 target price (down from $6.00) on shares of Bionano Genomics in a research report on Wednesday, August 28th.

Institutional Investors Weigh In On Bionano Genomics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Virtu Financial LLC bought a new position in Bionano Genomics in the 1st quarter worth about $36,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Bionano Genomics by 123.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock worth $79,000 after buying an additional 38,900 shares during the last quarter. Cantor Fitzgerald L. P. grew its position in Bionano Genomics by 22.2% in the fourth quarter. Cantor Fitzgerald L. P. now owns 55,000 shares of the company’s stock worth $104,000 after acquiring an additional 10,000 shares in the last quarter. Cetera Advisors LLC bought a new position in Bionano Genomics in the first quarter valued at $163,000. Finally, Quadrature Capital Ltd purchased a new stake in Bionano Genomics during the fourth quarter valued at about $209,000. 11.35% of the stock is owned by hedge funds and other institutional investors.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.